AcelRx Pharmaceuticals Inc. (ACRX) had a good day on the market for Friday November 29 as shares jumped 5.68% to close at $1.86. About 401,297 shares traded hands on 1,358 trades for the day, compared with an average daily volume of n/a shares out of a total float of 79.57 million. After opening the trading day at $1.77, shares of AcelRx Pharmaceuticals Inc. stayed within a range of $1.86 to $1.75.
With today’s gains, AcelRx Pharmaceuticals Inc. now has a market cap of $148.01 million. Shares of AcelRx Pharmaceuticals Inc. have been trading within a range of $4.09 and $1.64 over the last year, and it had a 50-day SMA of $n/a and a 200-day SMA of $n/a.
AcelRx Pharmaceuticals Inc is a specialty pharmaceutical company focused on the development and commercialization of therapies for use in medically supervised settings. The company’s proprietary, non-invasive sublingual formulation technology delivers sufentanil with consistent pharmacokinetic profiles. The company has one approved product in the U.S., DSUVIA (sufentanil sublingual tablet) known as DZUVEO in Europe indicated for the management of acute pain, severe enough to require an opioid analgesic for adult patients and one product candidate, Zalviso (sufentanil sublingual tablet system, SST system being developed as an innovatively designed patient-controlled analgesia (PCA) system for reduction of moderate-to-severe acute pain in medically supervised settings.
AcelRx Pharmaceuticals Inc. is based out of Redwood City, CA and has some 90 employees. Its CEO is Vincent J. Angotti.
AcelRx Pharmaceuticals Inc. is also a component of the Russell 2000. The Russell 2000 is one of the leading indices tracking small-cap companies in the United States. It’s maintained by Russell Investments, an industry leader in creating and maintaining indices, and consists of the smallest 2000 stocks from the broader Russell 3000 index.
Russell’s indices differ from traditional indices like the Dow Jones Industrial Average (DJIA) or S&P 500, whose members are selected by committee, because they base membership entirely on an objective, rules based methodology. The 3,000 largest companies by market cap make up the Russell 3000, with the 2,000 smaller companies making up the Russell 2000. It’s a simple approach that gives a broad, unbiased look at the small-cap market as a whole.
